{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T07:42:08Z","timestamp":1708760528528},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00105-023-05253-z","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:02:22Z","timestamp":1702630942000},"page":"256-267","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Januskinaseinhibitoren","Janus kinase inhibitors"],"prefix":"10.1007","volume":"75","author":[{"given":"Sophia","family":"von Martial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"12","key":"5253_CR1","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris\u00a0R, Kershaw\u00a0NJ, Babon\u00a0JJ (2018) The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci 27(12):1984\u20132009","journal-title":"Protein Sci"},{"issue":"3","key":"5253_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2021","unstructured":"Damsky\u00a0W, Peterson\u00a0D, Ramseier\u00a0J, Al-Bawardy\u00a0B, Chun\u00a0H, Proctor\u00a0D et al (2021) The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J\u00a0Allergy Clin Immunol 147(3):814\u2013826","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5253_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ddg.14668_g","volume":"20","author":"B Klein","year":"2022","unstructured":"Klein\u00a0B, Treudler\u00a0R, Simon\u00a0JC (2022) JAK-Inhibitoren in der Dermatologie \u2013 kleine Molek\u00fcle, gro\u00dfe Wirkung? \u00dcbersicht \u00fcber Wirkmechanismus, Studienergebnisse und m\u00f6gliche unerw\u00fcnschte Wirkungen. Jddg: J Dtsch Dermatologischen Ges 20(1):19\u201325. https:\/\/doi.org\/10.1111\/ddg.14668_g (German)","journal-title":"Jddg: J Dtsch Dermatologischen Ges"},{"issue":"11","key":"5253_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/ddg.14921_g","volume":"20","author":"A Eichner","year":"2022","unstructured":"Eichner\u00a0A, Wohlrab\u00a0J (2022) Pharmakologie der Januskinase-Inhibitoren \u2013 Teil\u00a01: Pharmakokinetik. J\u00a0Dtsch Dermatologischen Ges = J Ger Soc Dermatology : Jddg 20(11):1485\u20131500. https:\/\/doi.org\/10.1111\/ddg.14921_g (PMID: 36383971)","journal-title":"J Dtsch Dermatologischen Ges = J Ger Soc Dermatology : Jddg"},{"issue":"12","key":"5253_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz\u00a0DM, Kanno\u00a0Y, Villarino\u00a0A, Ward\u00a0M, Gadina\u00a0M, O\u2019Shea\u00a0JJ (2017) JAK inhibition as a\u00a0therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16(12):843\u2013862","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"5253_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","volume":"86","author":"JG Krueger","year":"2022","unstructured":"Krueger\u00a0JG, McInnes\u00a0IB, Blauvelt\u00a0A (2022) Tyrosine kinase\u00a02 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J\u00a0Am Acad Dermatol 86(1):148\u2013157","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"5253_CR7","first-page":"1621","volume":"20","author":"A Eichner","year":"2022","unstructured":"Eichner\u00a0A, Wohlrab\u00a0J (2022) Pharmakologie der Januskinase-Inhibitoren \u2013 Teil\u00a02: Pharmakodynamik: Pharmacology of inhibitors of Janus kinases\u2014Part 2: Pharmacodynamics. J\u00a0Dtsch Dermatologischen Ges = J Ger Soc Dermatology : JDDG 20(12):1621\u20131631","journal-title":"J Dtsch Dermatologischen Ges = J Ger Soc Dermatology : JDDG"},{"key":"5253_CR8","unstructured":"Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A et al S3-Leitlinie \u201eAtopische Dermatitis\u201c (AWMF-Registernr. 013-027). https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-0272023. Zugegriffen: 9. Aug. 2023"},{"key":"5253_CR9","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","year":"2018","unstructured":"Plewig\u00a0G, Landthaler\u00a0M, Burgdorf\u00a0WHC, Hertl\u00a0M, Ruzicka\u00a0TH (Hrsg) (2018) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer, Berlin"},{"key":"5253_CR10","doi-asserted-by":"crossref","unstructured":"Furue M (2020) Regulation of filaggrin, loricrin, and involucrin by IL\u20114, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci 21(15)","DOI":"10.3390\/ijms21155382"},{"issue":"1","key":"5253_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","volume":"50","author":"S Goenka","year":"2011","unstructured":"Goenka\u00a0S, Kaplan\u00a0MH (2011) Transcriptional regulation by STAT6. Immunol Res 50(1):87\u201396","journal-title":"Immunol Res"},{"issue":"2","key":"5253_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson\u00a0EL, Lacour\u00a0JP, Spelman\u00a0L, Galimberti\u00a0R, Eichenfield\u00a0LF, Bissonnette\u00a0R et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase\u00a0III trials. Br J Dermatol 183(2):242\u2013255","journal-title":"Br J Dermatol"},{"issue":"10246","key":"5253_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson\u00a0EL, Sinclair\u00a0R, Forman\u00a0S, Wollenberg\u00a0A, Aschoff\u00a0R, Cork\u00a0M et al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a\u00a0multicentre, double-blind, randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 396(10246):255\u2013266","journal-title":"Lancet"},{"issue":"3","key":"5253_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky\u00a0E, Tha\u00e7i\u00a0D, Pangan\u00a0AL, Hong\u00a0HC, Papp\u00a0KA, Reich\u00a0K et al (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a\u00a0randomized, placebo-controlled trial. J\u00a0Allergy Clin Immunol 145(3):877\u2013884","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"5253_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky\u00a0E, Teixeira\u00a0HD, Simpson\u00a0EL, Papp\u00a0KA, Pangan\u00a0AL, Blauvelt\u00a0A et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03\u00a0trials. Lancet 397(10290):2151\u20132168","journal-title":"Lancet"},{"issue":"2","key":"5253_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi\u00a0VY, Bhutani\u00a0T, Fonacier\u00a0L, Deleuran\u00a0M, Shumack\u00a0S, Valdez\u00a0H et al (2022) Phase\u00a03 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J\u00a0Am Acad Dermatol 87(2):351\u2013358","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"5253_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt\u00a0A, Teixeira\u00a0HD, Simpson\u00a0EL, Costanzo\u00a0A, De Bruin-Weller\u00a0M, Barbarot\u00a0S et al (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a\u00a0randomized clinical trial. Jama Dermatology 157(9):1047\u20131055","journal-title":"Jama Dermatology"},{"issue":"9","key":"5253_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing\u00a0L, Dai\u00a0Z, Jabbari\u00a0A, Cerise\u00a0JE, Higgins\u00a0CA, Gong\u00a0W et\u00a0al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049","journal-title":"Nat Med"},{"issue":"9","key":"5253_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas\u00a0E, Guttman-Yassky\u00a0E, Torres\u00a0T (2023) Baricitinib for the treatment of alopecia areata. Drugs 83(9):761\u2013770","journal-title":"Drugs"},{"issue":"3","key":"5253_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon\u00a0O, Senna\u00a0MM, Sinclair\u00a0R, Ito\u00a0T, Dutronc\u00a0Y, Lin\u00a0CY et al (2023) Efficacy and safety of baricitinib in patients with severe alopecia areata over 52\u00a0weeks of continuous therapy in two phase\u00a0III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol 24(3):443\u2013451","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"5253_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan\u00a0K, Sebaratnam\u00a0DF (2019) JAK inhibitors for alopecia areata: a\u00a0systematic review and meta-analysis. J\u00a0Eur Acad Dermatol Venereol 33(5):850\u2013856","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"5253_CR22","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1111\/jocd.15425","volume":"21","author":"E Behrangi","year":"2022","unstructured":"Behrangi\u00a0E, Barough\u00a0MS, Khoramdad\u00a0M, Hejazi\u00a0P, Koltapeh\u00a0MP, Goodarzi\u00a0A (2022) Efficacy and safety of tofacitinib for treatment of alopecia areata in children: a\u00a0systematic review and meta-analysis. J\u00a0Cosmet Dermatol 21(12):6644\u20136652","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"5253_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","volume":"86","author":"S Chapman","year":"2022","unstructured":"Chapman\u00a0S, Gold\u00a0LS, Lim\u00a0HW (2022) Janus kinase inhibitors in dermatology: part II. A\u00a0comprehensive review. J\u00a0Am Acad Dermatol 86(2):414\u2013422","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5253_CR24","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes\u00a0JE, Yan\u00a0BY, Chan\u00a0TC, Krueger\u00a0JG (2018) Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J\u00a0Immunol 201(6):1605\u20131613","journal-title":"J Immunol"},{"issue":"6","key":"5253_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","volume":"23","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9\u00a0AM, Puig\u00a0L, Torres\u00a0T (2022) Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol 23(6):813\u2013822","journal-title":"Am J Clin Dermatol"},{"key":"5253_CR26","doi-asserted-by":"crossref","unstructured":"Raychaudhuri S, Jayeshbhai Shah R, Raychaudhuri SK, Raychaudhuri SP (2023) Janus kinase inhibitors for the treatment of psoriatic arthritis. Indian J Dermatol Venereol Leprol 0:","DOI":"10.25259\/IJDVL_29_2023"},{"issue":"16","key":"5253_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D, Rigby\u00a0W, Azevedo\u00a0VF, Behrens\u00a0F, Blanco\u00a0R, Kaszuba\u00a0A et\u00a0al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"16","key":"5253_CR28","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease\u00a0P, Hall\u00a0S, FitzGerald\u00a0O, van der Heijde\u00a0D, Merola\u00a0JF, Avila-Zapata\u00a0F et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N\u00a0Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"3","key":"5253_CR29","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Schunter\u00a0JA, Fritz\u00a0K, Salavastru\u00a0C, Dargatz\u00a0S, Augustin\u00a0M et al (2022) S1-Leitlinie: Diagnostik und Therapie der Vitiligo. JDDG: J Dtsch Dermatologischen Ges 20(3):365\u2013379","journal-title":"JDDG: J Dtsch Dermatologischen Ges"},{"key":"5253_CR30","doi-asserted-by":"publisher","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"F Qi","year":"2021","unstructured":"Qi\u00a0F, Liu\u00a0F, Gao\u00a0L (2021) Janus kinase inhibitors in the treatment of vitiligo: a\u00a0review. Front Immunol 12:790125","journal-title":"Front Immunol"},{"issue":"16","key":"5253_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG, Grimes\u00a0P, Harris\u00a0JE, Desai\u00a0SR et\u00a0al (2022) Two phase\u00a03, randomized, controlled trials of ruxolitinib cream for vitiligo. N\u00a0Engl J Med 387(16):1445\u20131455","journal-title":"N Engl J Med"},{"issue":"4","key":"5253_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.18606","volume":"182","author":"P Mobasher","year":"2020","unstructured":"Mobasher\u00a0P, Guerra\u00a0R, Li\u00a0SJ, Frangos\u00a0J, Ganesan\u00a0AK, Huang\u00a0V (2020) Open-label pilot study of tofacitinib 2\u202f% for the treatment of refractory vitiligo. Br J Dermatol 182(4):1047\u20131049","journal-title":"Br J Dermatol"},{"issue":"4","key":"5253_CR33","doi-asserted-by":"publisher","first-page":"675.e1","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu\u00a0LY, Strassner\u00a0JP, Refat\u00a0MA, Harris\u00a0JE, King\u00a0BA (2017) Repigmentation in vitiligo using the janus kinase inhibitor tofacitinib may require concomitant light exposure. J\u00a0Am Acad Dermatol 77(4):675.e1\u2013682.e1","journal-title":"J Am Acad Dermatol"},{"key":"5253_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/CCID.S396430","volume":"16","author":"X Li","year":"2023","unstructured":"Li\u00a0X, Sun\u00a0Y, Du\u00a0J, Wang\u00a0F, Ding\u00a0X (2023) Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy. Clin Cosmet Investig Dermatol 16:635\u2013638","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7","key":"5253_CR35","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jdv.16464","volume":"34","author":"D Ioannides","year":"2020","unstructured":"Ioannides\u00a0D, Vakirlis\u00a0E, Kemeny\u00a0L, Marinovic\u00a0B, Massone\u00a0C, Murphy\u00a0R et\u00a0al (2020) European S1 guidelines on the management of lichen planus: a\u00a0cooperation of the european dermatology forum with the european academy of dermatology and venereology. J\u00a0Eur Acad Dermatol Venereol 34(7):1403\u20131414","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5253_CR36","doi-asserted-by":"crossref","unstructured":"Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R et al (2019) IFN\u2011\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus. Sci Transl Med 11(511)","DOI":"10.1126\/scitranslmed.aav7561"},{"key":"5253_CR37","doi-asserted-by":"crossref","unstructured":"Abduelmula A, Bagit A, Mufti A, Yeung KCY, Yeung J (2023) The use of janus kinase inhibitors for lichen planus: an evidence-based review. J\u00a0Cutan Med Surg 12034754231156100:","DOI":"10.1177\/12034754231156100"},{"issue":"1","key":"5253_CR38","first-page":"187","volume":"93","author":"A Wang","year":"2020","unstructured":"Wang\u00a0A, Singh\u00a0K, Ibrahim\u00a0W, King\u00a0B, Damsky\u00a0W (2020) The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a\u00a0review of the literature. Yale J Biol Med 93(1):187\u2013195","journal-title":"Yale J Biol Med"},{"issue":"5","key":"5253_CR39","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jaci.2020.10.012","volume":"147","author":"A Wang","year":"2021","unstructured":"Wang\u00a0A, Rahman\u00a0NT, McGeary\u00a0MK, Murphy\u00a0M, McHenry\u00a0A, Peterson\u00a0D et\u00a0al (2021) Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J\u00a0Allergy Clin Immunol 147(5):1795\u20131809","journal-title":"J Allergy Clin Immunol"},{"key":"5253_CR40","doi-asserted-by":"crossref","unstructured":"Sood S, Heung M, Georgakopoulos JR, Mufti A, Prajapati VH, Yeung J (2023) Use of Janus kinase inhibitors for granulomatous dermatoses: a\u00a0systematic review. J\u00a0Am Acad Dermatol","DOI":"10.1016\/j.jaad.2023.03.024"},{"issue":"1","key":"5253_CR41","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","volume":"13","author":"W Damsky","year":"2022","unstructured":"Damsky\u00a0W, Wang\u00a0A, Kim\u00a0DJ, Young\u00a0BD, Singh\u00a0K, Murphy\u00a0MJ et\u00a0al (2022) Inhibition of type\u00a01 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun 13(1):3140","journal-title":"Nat Commun"},{"issue":"9","key":"5253_CR42","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees\u00a0C, Tomcik\u00a0M, Palumbo-Zerr\u00a0K, Distler\u00a0A, Beyer\u00a0C, Lang\u00a0V et al (2012) JAK\u20112 as a\u00a0novel mediator of the profibrotic effects of transforming growth factor\u00a0\u03b2 in systemic sclerosis. Arthritis Rheum 64(9):3006\u20133015","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5253_CR43","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","volume":"60","author":"H You","year":"2021","unstructured":"You\u00a0H, Xu\u00a0D, Hou\u00a0Y, Zhou\u00a0J, Wang\u00a0Q, Li\u00a0M et\u00a0al (2021) Tofacitinib as a\u00a0possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatol (Oxford) 60(5):2472\u20132477","journal-title":"Rheumatol (Oxford)"},{"issue":"5","key":"5253_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim\u00a0SR, Charos\u00a0A, Damsky\u00a0W, Heald\u00a0P, Girardi\u00a0M, King\u00a0BA (2018) Treatment of generalized deep morphea and eosinophilic fasciitis with the janus kinase inhibitor tofacitinib. Jaad Case Reports 4(5):443\u2013445","journal-title":"Jaad Case Reports"},{"issue":"6","key":"5253_CR45","doi-asserted-by":"publisher","first-page":"e15437","DOI":"10.1111\/dth.15437","volume":"35","author":"S McGaugh","year":"2022","unstructured":"McGaugh\u00a0S, Kallis\u00a0P, De Benedetto\u00a0A, Thomas\u00a0RM (2022) Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a\u00a0literature review. Dermatol Ther 35(6):e15437","journal-title":"Dermatol Ther"},{"key":"5253_CR46","doi-asserted-by":"publisher","first-page":"1158768","DOI":"10.3389\/fmed.2023.1158768","volume":"10","author":"G La Rocca","year":"2023","unstructured":"La Rocca\u00a0G, Ferro\u00a0F, Baldini\u00a0C, Libra\u00a0A, Sambataro\u00a0D, Colaci\u00a0M et\u00a0al (2023) Targeting intracellular pathways in idiopathic inflammatory myopathies: a\u00a0narrative review. Front Med 10:1158768","journal-title":"Front Med"},{"issue":"2","key":"5253_CR47","first-page":"348","volume":"41","author":"JJ Paik","year":"2023","unstructured":"Paik\u00a0JJ, Lubin\u00a0G, Gromatzky\u00a0A, Mudd\u00a0PN Jr., Ponda\u00a0MP, Christopher-Stine\u00a0L (2023) Use of Janus kinase inhibitors in dermatomyositis: a\u00a0systematic literature review. Clin Exp Rheumatol 41(2):348\u2013358","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5253_CR48","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","volume":"73","author":"JJ Paik","year":"2021","unstructured":"Paik\u00a0JJ, Casciola-Rosen\u00a0L, Shin\u00a0JY, Albayda\u00a0J, Tiniakou\u00a0E, Leung\u00a0DG et al (2021) Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol (Hoboken, NJ) 73(5):858\u2013865","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"8","key":"5253_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJB Kurtzman","year":"2016","unstructured":"Kurtzman\u00a0DJB, Wright\u00a0NA, Lin\u00a0J, Femia\u00a0AN, Merola\u00a0JF, Patel\u00a0M et\u00a0al (2016) Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. Jama Dermatology 152(8):944\u2013945","journal-title":"Jama Dermatology"},{"key":"5253_CR50","doi-asserted-by":"crossref","unstructured":"Niebel D, de Vos L, Fetter T, Br\u00e4gelmann C, Wenzel J (2023) Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol: 1\u201320","DOI":"10.1007\/s40257-023-00774-8"},{"issue":"4","key":"5253_CR51","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/ced.15005","volume":"47","author":"L Joos","year":"2022","unstructured":"Joos\u00a0L, Vetterli\u00a0F, Jaeger\u00a0T, Cozzio\u00a0A, von Kempis\u00a0J, Rubbert-Roth\u00a0A (2022) Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol 47(4):748\u2013750","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"5253_CR52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/ced.15044","volume":"47","author":"A Kreuter","year":"2022","unstructured":"Kreuter\u00a0A, Licciardi-Fernandez\u00a0MJ, Burmann\u00a0SN, Paschos\u00a0A, Michalowitz\u00a0AL (2022) Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol 47(4):787\u2013788","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"5253_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, Koskinas\u00a0KC, Casula\u00a0M, Badimon\u00a0L et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"11","key":"5253_CR54","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/1346-8138.16116","volume":"48","author":"PH Chang","year":"2021","unstructured":"Chang\u00a0PH, Huang\u00a0SF, Chang\u00a0PS, Yu\u00a0Y (2021) Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J\u00a0Dermatol 48(11):1631\u20131639","journal-title":"J Dermatol"},{"issue":"1","key":"5253_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong\u00a0AW, Gooderham\u00a0M, Warren\u00a0RB, Papp\u00a0KA, Strober\u00a0B, Tha\u00e7i\u00a0D et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1\u00a0trial. J\u00a0Am Acad Dermatol 88(1):29\u201339","journal-title":"J Am Acad Dermatol"},{"key":"5253_CR56","doi-asserted-by":"crossref","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A et al (2023) Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9(1)","DOI":"10.1136\/rmdopen-2022-002735"},{"issue":"1","key":"5253_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober\u00a0B, Tha\u00e7i\u00a0D, Sofen\u00a0H, Kircik\u00a0L, Gordon\u00a0KB, Foley\u00a0P et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase\u00a03 program for evaluation of TYK2 inhibitor psoriasis second trial. J\u00a0Am Acad Dermatol 88(1):40\u201351","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"5253_CR58","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King\u00a0B, Ohyama\u00a0M, Kwon\u00a0O, Zlotogorski\u00a0A, Ko\u00a0J, Mesinkovska\u00a0NA et\u00a0al (2022) Two phase\u00a03 trials of baricitinib for alopecia areata. N\u00a0Engl J Med 386(18):1687\u20131699","journal-title":"N Engl J Med"},{"issue":"4","key":"5253_CR59","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR, Koch\u00a0GG, Fleischmann\u00a0R, Rivas\u00a0JL et\u00a0al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"key":"5253_CR60","unstructured":"DGRh. Deutsche Gesellschaft f\u00fcr Rheumatologie e. V. Therapieinformationsb\u00f6gen f\u00fcr Patienten und \u00c4rzte zum Ausdrucken. https:\/\/dgrh.de\/Start\/Versorgung\/Therapieinformationen\/Therapieinformationsb%C3%B6gen.html2023. Zugegriffen: 9. Aug. 2023"},{"issue":"1","key":"5253_CR61","first-page":"201","volume":"10","author":"CA Salinas","year":"2023","unstructured":"Salinas\u00a0CA, Louder\u00a0A, Polinski\u00a0J, Zhang\u00a0TC, Bower\u00a0H, Phillips\u00a0S et al (2023) Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a\u00a0multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther 10(1):201\u2013223","journal-title":"Rheumatol Ther"},{"key":"5253_CR62","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Version\u00a03\/Stand: September 2021 Checkliste zur Verringerung von Arzneimittel- und Anwendungsrisiken \u2013 \u00c4rztinnen und \u00c4rzte. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/EducationMaterial\/Anlagen\/kombinierte-hormonelle-kontrazeptiva-aerzte.html;jsessionid=82F7FBFF313E91285582CA8D11224886.internet272?nn=4712742023"},{"key":"5253_CR63","unstructured":"European medicine agency. Janus kinase inhibitors (JAKi). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki2023. Zugegriffen: 9. Juni 2023"},{"key":"5253_CR64","unstructured":"American college of cardiology. ASCVD risk estimator plus. https:\/\/tools.acc.org\/ascvd-risk-estimator-plus\/#!\/calculate\/estimate\/2021. Zugegriffen: 9. Juni 2023"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05253-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T07:03:11Z","timestamp":1708758191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05253-z"}},"subtitle":["Indikationen, Wirkung, Einsatz: Was ist zu beachten?","Indications, efficacy, uses, what should be taken into account?"],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5253"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05253-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"18 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00105-024-05307-w","URL":"https:\/\/doi.org\/10.1007\/s00105-024-05307-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0von Martial<\/b>: A.\u00a0Finanzielle Interessen: S.\u00a0von Martial gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin Dermatologie, Fachklinik Bad Bentheim | Mitgliedschaften: BVDD, DDG. <b>A.\u00a0Tsianakas<\/b>: A.\u00a0Finanzielle Interessen: Honorare f\u00fcr Vortr\u00e4ge: Pfizer, AbbVie, Eli Lilly, BMS.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Vorsitz Arbeitsgemeinschaft Rehabilitation in der Dermatologie | Chefarzt Dermatologie, Fachklinik Bad Bentheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}